Source: Google NewsPublished on 2020-12-30
Related Articles:
- Rehabilitation Is About a Path to Well-being Using a Total Health Approach March 1, 2019 Rehabilitation, the “R” in the CHRONDI Creed, is about the path to well-being. It is an action plan aimed at doing all that is possible to live well with a chronic disease. A well-designed rehab plan can make that journey easier. Think of a rehab plan as an expanded treatment plan that includes not just symptom treatment, but also all…
- Acadia Supports Events to Mark Parkinson’s Disease Awareness Month in U.S. April 16, 2019 Acadia Pharmaceuticals is marking Parkinson’s Awareness Month by supporting a host of events and activities in April throughout the U.S. Although some events have occurred, several are annual events needing participation. “We encourage patients and their families to attend an event, which includes important resources to help them navigate their unique journey with Parkinson’s,” said Steve Davis, Acadia’s CEO, in…
- UPDATE 1-Acadia to sell UK unit for $1.47 bln to Waterland Private Equity - Reuters December 30, 2020 UPDATE 1-Acadia to sell UK unit for $1.47 bln to Waterland Private Equity Reuters
- Nuplazid ‘Significantly’ Slows Relapses in Dementia-Related Psychosis, Phase 3 Trial Shows October 7, 2019 Interim results from the ongoing Phase 3 HARMONY study show that treatment with Nuplazid (pimavanserin) significantly delays time to a psychosis relapse in patients with dementia-related disorders, such as Parkinson’s and Alzheimer’s disease. Evaluation by an independent data monitoring committee recommended an early stop to this placebo-controlled trial based on the treatment’s “robust” efficacy, Acadia Pharmaceuticals — Nuplazid’s manufacturer — announced in a…
- Rehab hospital slated for Carmel, but operator has been closing other locations - Indianapolis Business Journal May 13, 2019 Rehab hospital slated for Carmel, but operator has been closing other locations Indianapolis Business JournalAnother rehabilitation hospital is planned for central Indiana, but one of the developers has been cutting hundreds of jobs and shutting down other hospitals ...
- New Phase 3 Trial to Test Nuplazid for Parkinson’s Psychosis in Array of Dementia Patients October 5, 2017 Acadia Pharmaceuticals is starting a new Phase 3 clinical trial testing the efficacy of pimavanserin to treat the hallucinations and delusions associated with dementia-related psychosis in a broad array of patients with Parkinson’s, Alzheimer’s, and many other dementias. Pimavanserin, under the brand name Nuplazid, was approved by the U.S. Food and Drug Administration (FDA) to treat dementia-related psychosis in Parkinson’s patients in 2016. This trial, and the Breakthrough…
- FDA Continuing to Monitor Nuplazid Use, Agency Says in Response to Controversial CNN Report April 16, 2018 The U.S. Food and Drug Administration is keeping close watch on the use of Nuplazid (pimavanserin) by Parkinson’s patients with disease-related psychosis, but at present sees no reasons to change the existing warnings placed on the medication — sold by Acadia Pharmaceuticals — when first approved. The FDA stated its position, given in response to a recent CNN report on patient…
- Benefits of Acadia’s Nuplazid Outweigh Risks for Parkinson’s Psychosis Patients, FDA Reports September 24, 2018 Nearly half a year after news reports surfaced about deaths allegedly linked to Nuplazid (pimavanserin) — a therapy for Parkinson’s patients with disease-related psychosis — the U.S. Food and Drug Administration says it could not find any new or unexpected safety concerns with the controversial treatment. The agency said in a Sept. 20 press release that “after a thorough review, the FDA’s…
- Nuplazid Eases Depression in Parkinson’s Patients, Phase 2 Trial Shows October 1, 2019 Treatment with Nuplazid (pimavanserin), approved in the U.S. for treating hallucinations and delusions associated with Parkinson’s psychosis, eased depression and sleep problems in patients with Parkinson’s, according to results from a Phase 2 clinical trial. The research, “Open-Label Study of Pimavanserin Patients With Comorbid Parkinson’s Disease and Depression,” was presented at the 2019 International Congress of Parkinson’s Disease and Movement Disorders in Nice,…
- Nuplazid Shows Sustained Easing of Psychosis in Patients in Phase 3 Trial June 8, 2020 Daily use of Nuplazid (pimavanserin) leads to strong and sustained reductions in the frequency and severity of hallucinations and delusions in people with Parkinson’s disease psychosis, according to data from a long-term extension study. These findings, “Improvement and Durability in SAPS-PD Assessment over 10 Weeks of Pimavanserin Treatment for Parkinson’s Disease Psychosis,” were presented at the at the 2020 American…
- Nuplazid’s Risks in Treating Parkinson’s Psychosis Don’t Appear Exceptionally High, Experts Say June 11, 2018 The controversy surrounding Nuplazid (pimavanserin), Acadia Pharmaceuticals‘ approved treatment for psychosis in Parkinson’s patients, has made its way to scientific journals. But experts appear to take a more questioning view of the medication’s risks than that aired by general media. A clinical trial comparing the effectiveness and benefits of Nuplazid to other antipsychotics used to treat these patients would be warranted, and ideally…
- Once-a-day Capsule for Nuplazid and Lower Dose Option Approved for Parkinson’s Psychosis Patients July 2, 2018 The U.S. Food and Drug Administration has approved a once-a-day capsule formulation and a lower tablet strength for Nuplazid (pimavanserin), a treatment for the hallucinations and delusions associated with Parkinson’s psychosis. The new formulation — a 34 mg capsule— enables patients to take the recommended oral dose once a day instead of the twice-daily existing 17-mg tablet dose. Also approved…
- How Language Creates Disease April 12, 2020 The human brain is wired for, and by, language. It is how we get ideas from one mind into another. Our languages have separated us into discreet cultural bubbles that we often can not see past. Though most have shared roots, cultural gaps tend to be greater between languages that diverged longer ago. All of our knowledge about the world…
- How Language Creates Disease April 12, 2020 The human brain is wired for, and by, language. It is how we get ideas from one mind into another. Our languages have separated us into discreet cultural bubbles that we often can not see past. Though most have shared roots, cultural gaps tend to be greater between languages that diverged longer ago. All of our knowledge about the world…
- How Language Creates Disease April 12, 2020 The human brain is wired for, and by, language. It is how we get ideas from one mind into another. Our languages have separated us into discreet cultural bubbles that we often can not see past. Though most have shared roots, cultural gaps tend to be greater between languages that diverged longer ago. All of our knowledge about the world…
- How Language Creates Disease April 12, 2020 The human brain is wired for, and by, language. It is how we get ideas from one mind into another. Our languages have separated us into discreet cultural bubbles that we often can not see past. Though most have shared roots, cultural gaps tend to be greater between languages that diverged longer ago. All of our knowledge about the world…
- Celebrity boxing champ coaches Grand Strand kids, teens, people with disabilities - WBTW - Myrtle Beach and Florence SC November 27, 2018 WBTW - Myrtle Beach and Florence SCCelebrity boxing champ coaches Grand Strand kids, teens, people with disabilitiesWBTW - Myrtle Beach and Florence SCSURFSIDE BEACH, SC (WBTW) - A celebrity boxing champion is making his sport affordable for children and teens on the Grand Strand. Todd "The ... He also trains people with heart issues, Parkinson's disease and other disabilities. Poulton…
- Meritus total rehab care offers speech program for people with Parkinson’s - WDVM 25 June 27, 2019 Meritus total rehab care offers speech program for people with Parkinson’s WDVM 25HAGERSTOWN, Md. (WDVM) — Meritus Medical Center in Hagerstown has a total rehab center that offers therapy to people with Parkinson's. Its program ...
- Study Reviews Use of Acadia’s Nuplazid as Treatment for Psychosis Linked to Parkinson’s Disease June 19, 2017 Acadia Pharmaceuticals‘ Nuplazid (pimavanserin) is a reliable treatment to manage hallucinations and delusions associated with Parkinson’s disease psychosis (PDP), but its high cost and restricted access may limit its use in clinical practice, a new study says. The review, “Pimavanserin: A Novel Antipsychotic for Parkinson’s Disease Psychosis,” appeared in the journal Annals of Pharmacotherapy. Pimavanserin is a selective serotonin inverse…
- Forbes Includes Maker of Nuplazid on List of Most Innovative Growth Companies July 27, 2017 Acadia Pharmaceuticals, the maker of Nuplazid (pimavanserin), an oral medication to treat hallucinations and delusions associated with Parkinson’s disease (PD), was ranked 11th on Forbes Magazine’s 2017 list of the “World’s Most Innovative Growth Companies.” Forbes’ ranking is based on the ‘innovation premium’ of each company and includes only industries that invest in innovative solutions. An innovation premium, according to…
- Most Parkinson’s Patients Show Non-movement Symptoms Like Depression, Sleep Problems, Survey Finds April 26, 2018 Nearly all Parkinson’s disease patients experience non-movement symptoms, such as sleep disturbances or depression, which affect their quality of life as much as movement-related symptoms, according to an online survey of 700 participants, nearly 600 of whom completed it in full. Patients’ caregivers are those most likely to detect non-movement manifestations of the disease. These are the two main conclusion of…
- Acadia: Cascading Catalysts - Seeking Alpha May 6, 2019 Acadia: Cascading Catalysts Seeking AlphaAcadia's existing revenue trajectory from its FDA approved Nuplazid therapy is growing nicely but requires significant supplementation. Acadia's calendar is hea.